- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on CV Therapeutics Inc. (CVTX)
by latest | most commented
-
Health Care Trends Part 2: M&A, Generic Competition, CROs
-
A Look at M & A Arbitrage Activity
-
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
-
Where Might Genentech Investors Redeploy $47B?
-
Big Mergers Could Mean Sweet Gains for Biotech
-
Biotech Is Now the Place to Be for Big Pharma
-
Gilead Follows Its Heart, Sweeps CV Away for $1.4B
-
Why Is Gilead Buying CV Therapeutics?
-
Thursday's Options Recap
-
CV Tells Astellas to Take a Hike: Looks to Gilead
-
Astellas Announces Offer to Buy CV Therapeutics
-
Know Your Options When Investing in Biotech Stocks
-
Ugly Stock Stats from an Ugly Bear
-
71 Stocks Leading the Nasdaq Higher
-
Bullish Thesis for Biotech Remains Intact
-
Will CV Therapeutics Get a Higher Price from Astellas?
-
Wednesday Options Update: UTX, GE, USB, WMT, NTRS, BK & CVTX
-
Looking for the Biotech Breakout
-
New Index of Health Product Innovators
-
New Emerging Biotech and Pharma Company Index
-
Rigel Pharmaceuticals: Biotech Crisis or Opportunity?
-
Thursday Options Update: LVS, CSCO, NWS, CVTX, BAC & WMT
-
'When There's Blood in the Streets', Buy Biotech Stocks
-
Will M&A Activity Boost PowerShares Dynamic Biotech & Genome ETF?
-
Monday's Options Report: BSC, LEH, XLF, ACAS, VIX, CFC, CVTX
-
Loeb's Third Point Issues Latest 13F: Summary of Holdings
-
Earnings Preview: Five Companies That Could Surprise
-
Screening for Potential Buyout Targets
-
CV Therapeutics: Loeb's Third Point Discloses 9.9% Stake
-
Loeb's Third Point Releases 13F Filing, Shows a Number of New Positions
-
The Next Great Biotech Short Squeeze
-
Biotech Day In Review: Regeneron Up On AMD Data
-
Why the CV Therapeutics Sell-off Was Overdone
-
Ranexa Won't Treat Heart Attacks, CV Therapeutics Falls 24%
-
Biotech Day in Review: Avalon Signs $200 Million Deal with Merck
-
CV Therapeutics Trial Results: Enough To Drive Profitability?
-
Will MERLIN Work Magic For CV Therapeutics?
-
CV Therapeutics: Last Chance for a Tax Loss
-
Biotech Portfolio Overview: PDL Biopharm Still Cheap, CV Therapeutics Still Falling
-
Biotech Bloodletting: CV Therapeutics and Vertex Pharmaceuticals (CVTX, VRTX)